2,809 AbbVie Inc. $ABBV Shares Sold by EagleClaw Capital Managment LLC

EagleClaw Capital Managment LLC trimmed its holdings in AbbVie Inc. (NYSE:ABBV) by 3.9% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 68,965 shares of the company’s stock after selling 2,809 shares during the quarter. AbbVie accounts for about 2.4% of EagleClaw Capital Managment LLC’s holdings, making the stock its 7th biggest holding. EagleClaw Capital Managment LLC’s holdings in AbbVie were worth $18,041,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in ABBV. Verus Financial Partners Inc. boosted its stake in shares of AbbVie by 1.7% during the third quarter. Verus Financial Partners Inc. now owns 2,048 shares of the company’s stock valued at $536,000 after purchasing an additional 35 shares during the period. Evergreen Private Wealth LLC grew its holdings in shares of AbbVie by 3.3% in the third quarter. Evergreen Private Wealth LLC now owns 1,090 shares of the company’s stock worth $285,000 after purchasing an additional 35 shares during the last quarter. Lifelong Wealth Advisors Inc. increased its stake in shares of AbbVie by 2.1% in the third quarter. Lifelong Wealth Advisors Inc. now owns 1,755 shares of the company’s stock worth $459,000 after buying an additional 36 shares during the period. IMG Wealth Management Inc. increased its stake in shares of AbbVie by 22.8% in the third quarter. IMG Wealth Management Inc. now owns 194 shares of the company’s stock worth $51,000 after buying an additional 36 shares during the period. Finally, Foundry Financial Group Inc. increased its stake in shares of AbbVie by 4.6% in the third quarter. Foundry Financial Group Inc. now owns 839 shares of the company’s stock worth $219,000 after buying an additional 37 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Trading Up 0.2%

Shares of NYSE ABBV opened at $295.18 on Friday. The firm has a fifty day simple moving average of $275.51 and a two-hundred day simple moving average of $240.91. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $302.93. The firm has a market capitalization of $521.76 billion, a PE ratio of 50.81, a price-to-earnings-growth ratio of 1.34 and a beta of 0.20.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.73 by $0.09. The company had revenue of $17.40 billion for the quarter, compared to analysts’ expectations of $17.32 billion. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. AbbVie’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.86 earnings per share. On average, sell-side analysts predict that AbbVie Inc. will post 13.98 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be given a dividend of $1.82 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date of this dividend is Friday, January 15th. This represents a $7.28 dividend on an annualized basis and a yield of 2.5%. AbbVie’s dividend payout ratio is 125.30%.

AbbVie News Summary

Here’s some of the latest news about ABBV:

• Positive Sentiment: AbbVie’s immunology sales grew 16.6% in the third quarter, led by Skyrizi and Rinvoq. Their momentum is helping lift sales expectations for 2026, although Humira continues to decline. How Did AbbVie’s Immunology Franchise Fare in Q3?
• Positive Sentiment: AbbVie licensed Nxera Pharma’s EP4 agonist program for inflammatory bowel disease. The deal adds a potential pipeline asset, though its milestones depend on future development and other conditions. AbbVie Deal Altering the Investment Case for Nxera Pharma
• Negative Sentiment: EVP Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81%. The sale could weigh on sentiment, though the filing did not state a reason. AbbVie EVP Sells $11,925,738.40 in Stock

Insider Buying and Selling

In other AbbVie news, EVP Jeffrey Stewart sold 40,619 shares of the company’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $293.60, for a total value of $11,925,738.40. Following the sale, the executive vice president owned 83,171 shares in the company, valued at approximately $24,419,005.60. This represents a 32.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is owned by insiders.

Analysts Set New Price Targets

ABBV has been the subject of several analyst reports. Piper Sandler increased their price target on shares of AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a research report on Thursday, August 20th. Rothschild & Co Redburn boosted their price objective on shares of AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Bank of America reaffirmed a “buy” rating on shares of AbbVie in a research note on Tuesday, September 8th. BNP Paribas Exane increased their target price on shares of AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a report on Tuesday, August 11th. Finally, Guggenheim increased their target price on shares of AbbVie from $288.00 to $322.00 and gave the stock a “buy” rating in a report on Monday, November 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $297.46.

AbbVie Profile

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.